Dimebon (PF-01913539)-Digoxin Drug-Drug Interaction Study In Healthy Subjects
Status:
Completed
Trial end date:
2009-05-01
Target enrollment:
Participant gender:
Summary
This study has been designed to confirm, in healthy subjects, the lack of a clinically
important pharmacokinetic interaction between Dimebon, at the proposed maximum commercial
dose of 20 mg TID (administered every 8 hours), and digoxin (Lanoxin®) 0.125 mg QD, a
sensitive P-gp substrate recommended by FDA.